* Pieris Pharmaceuticals Inc PIRS.OQ PIRS.O is expected
to show a rise in quarterly revenue when it reports results on
August 2 (estimated).
* The Boston Massachusetts-based company is expected to
report a
218.8% increase in revenue to $10.471 million from $3.29 million
a year ago, according to the mean estimate from 2 analysts,
based on Refinitiv data.
* Refinitiv's mean analyst estimate for Pieris
Pharmaceuticals
Inc is for a loss of 11 cents per share. For the same quarter
last year, the company reported a loss of 25 cents per share.
* The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 2 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
This summary was machine generated July 29 at 16:42 GMT. All
figures in US dollars unless otherwise stated